HIV type 1 antiretroviral resistance mutations in subtypes B, C, and F in the City of São Paulo, Brazil

AIDS Research and Human Retroviruses

Volumn 26, Issue 3, 2010, Pages 265-273

  Munerato, Patricia ^a   Sucupira, Maria Cecilia ^a   Oliveros, Márcia P R ^b   Janini, Luiz Mario ^c   De Souza, Denise Ferreira ^c   Pereira, Anderson Alvarenga ^c   Inocencio, Lilian Amaral ^c   Diaz, Ricardo Sobhie ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c MINISTÉRIO DA SAÚDE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR; EFAVIRENZ; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TIPRANAVIR;

ANTIVIRAL RESISTANCE; ARTICLE; BLOOD SAMPLING; BRAZIL; CLINICAL TRIAL; CROSS RESISTANCE; GENETIC VARIABILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE B; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE C; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE F; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS LOAD; VIRUS MUTATION; VIRUS STRAIN;

EID: 77950275095     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0288     Document Type: Article

References (35)

1. Medeiros R, Diaz RS, and Filho AC: Estimating the length of the first antiretroviral therapy regiment durability in Sao Paulo, Brazil. Braz J Infect Dis 2002;6:298-304.
2. Caseiro MM, Golegã AAC, Etzel A, and Diaz RS: Characterization of virologic failure after an initially successful 48-week course of antiretroviral therapy in HIV=AIDS outpatients treated in Santos, Brazil. Braz J Infect Dis 2008;12:162-166.
3. Sucupira MC, Caseiro MM, Alves K, Tescarollo G, Janini LM, Sabino EC, et al.: High levels of primary antiretroviral resistance genotypic mutations and B=F recombinants in Santos, Brazil. AIDS Patient Care STDS 2007;21:116-128.
4. Apetrei C, Loussert-Ajaka I, Descamps D, Damond F, Saragosti S, Brun-Vezinet F, and Simon F: Lack of screening test sensitivity during HIV-1 non-subtype B seroconversions. AIDS 1996;10:F57-F60.
5. Burgisser P, Vernazza P, Flepp M, Boni J, Tomasik Z, Hummel U, et al.: Performance of five different assays for the quantification of viral load in persons infected with various subtypes of HIV-1. Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2000;23:138-144.
6. Kaleebu P, Ross A, Morgan D, Yirrell D, Oram J, Rutebemberwa A, et al.: Relationship between HIV-1 Env subtypes A and D and disease progression in a rural Ugandan cohort. AIDS 2001;15:293-299.
7. Kanki PJ, Hamel DJ, Sankale JL, Hsieh C, Thior I, Barin F, et al.: Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 1999;179:68-73.
8. Maggiolo F, Callegaro A, Laura R, Ripamonti D, Gregis G, Quinzan G, et al.: Resistance Conferring Mutations in B Versus non-B HIV Clades After Treatment Failure. Seventh International Congress on Drug Therapy in HIV Infection. Glasgow, UK, 14-17 November 2004.
9. Sucupira MC, Souza IE, Costa LJ, Scheinberg MA, and Diaz RS: Antiretroviral treatment failure and HIV-1 genotypic resistance in Sao Paulo, Brazil. Antivir Ther 2001;6:263-264.
10. Brenner B, TurnerD,OliveiraM,Moisi D,DetorioM,Carobene M, et al.: A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003;17:F1-F5.
11. Gonzalez LM, Brindeiro RM, Tarin M, Calazans A, Soares MA, Cassol S, and Tanuri A: In vitro hypersusceptibility of human immunodeficiency virus type 1 subtype C protease to lopinavir. Antimicrob Agents Chemother 2003;47:2817-2822.
12. Brenner BG, Oliveira M, Doualla-Bell F, Moisi DD, Ntemgwa M, Frankel F, et al.: HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 2006;20:F9-F13.
13. Johnson VA, Brun-Vézinet F, Clotet B, Gü nthard HF, Kuritzkes DR, Pillay D, et al.: Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 2007;15:119-125.
14. Cozzi-Lepri A, Ruiz L, Loveday C, Phillips AN, Clotet B, Reiss P, et al.: Thymidine analogue mutation profiles: Factors associated with acquiring specific profiles and their impact on the virological response to therapy. Antivir Ther 2005;10: 791-802.
15. Rawal BD, Degula A, Lebedeva L, Janssen RS, Hecht FM, Sheppard HW, and Busch MP: Development of a new lesssensitive enzyme immunoassay for detection of early HIV-1 infection. J Acquir Immune Defic Syndr 2003;33:349-355.
16. Zaccarelli M, Tozzi V, Lorenzini P, Trotta MP, Forbici F, Visco-Comandini U, et al.: Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS 2005;19:1081-1089.
17. Rodrigues R, Vazquez CM, Colares JK, Custodio RM, Bonasser Filho F, Souza Ldo R, et al.: Antiretroviral resistance mutations in human immunodeficiency virus type 1 infected patients enrolled in genotype testing at the Central Public Health Laboratory, São Paulo, Brazil: Preliminary results. Mem Inst Oswaldo Cruz 2005;100:97-102.
18. Couto-Fernandez JC, Silva-de-Jesus C, Veloso VG, Rachid M, Gracie RS, Chequer-Fernandez SL, et al.: Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio ]de Janeiro, Brazil: Assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy. Mem Inst Oswaldo Cruz 2005;100:73-78.
19. Leal E ML, Janini LM, and Diaz RS: Evolutionary dynamics of HIV-1 BF and CB recombinants and its parental counterparts in South America. Retrovirology 2008;1:1-14.
20. Soares EA, Santos AF, Sousa TM, Sprinz E, Martinez AM, Silveira J, et al.: Differential drug resistance acquisition in HIV-1 of subtypes B and C. PLoS ONE 2007;2:e730.
21. Santos AF, Lengruber RB, Soares EA, Jere A, Sprinz E, Martinez AM, et al.: Conservation patterns of HIV-1 RT connection and RNase H domains: Identification of new mutations in NRTI-treated patients. PLoS ONE 2008;3:e1781.
22. Yap SH, Sheen CW, Fahey J, Zanin M, Tyssen D, Lima VD, et al.: N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med 2007;4:e335.
23. Calazans A, Brindeiro R, Brindeiro P, Verli H, Arruda MB, Gonzalez LM, et al.: Low accumulation of L90M in protease from subtype F HIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism. J Infect Dis 2005; 191:1961-1970.
24. Diaz RS, Vasconcelos L, Hayden RL, Tenore S, Turcato G, Jr., Palacios R, and Sucupira MC: Similar efficacy of lopinavir= ritonavir-containing regimens among clades B and F HIV-1- infected individuals in Brazil. J Acquir Immune Defic Syndr 2008;47:399-401.
25. Perrin V and Mammano F: Parameters driving the selection of nelfinavir-resistant human immunodeficiency virus type 1 variants. J Virol 2003;77:10172-10175.
26. Clotet B, Ruiz L, Martinez-Picado J, Negredo E, Hill A, and Popescu M: Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: A retrospective analysis of four clinical studies and two observational cohorts. HIV Clin Trials 2002;3:316-323.
27. Miller MD, Margot N, Lu B, Zhong L, Chen SS, Cheng A, and Wulfsohn M: Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 2004;189:837-846.
28. Hanna GJ, Johnson VA, Kuritzkes DR, Richman DD, Brown AJ, Savara AV, et al.: Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J Infect Dis 2000;181:904-911.
29. Yahi N, Tamalet C, Tourres C, Tivoli N, Ariasi F, Volot F, et al.: Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1- infected patients undergoing combination therapy: Survey of 787 sequences. J Clin Microbiol 1999;37:4099-4106.
30. Parikh UM, Bacheler L, Koontz D, and Mellors JW: The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol 2006; 80:4971-4977.
31. Parikh UM, Barnas DC, Faruki H, and Mellors JW: Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level. J Infect Dis 2006;194:651-660.
32. Deeks SG and Grant RM: Sustained CD4 responses after virological failure of protease inhibitor-containing therapy. Antivir Ther 1999;4(Suppl 3):7-11.
33. Hunt PW, Deeks SG, Bangsberg DR, Moss A, Sinclair E, Liegler T, et al.: The independent effect of drug resistance on T cell activation in HIV infection. AIDS 2006;20:691-699.
34. Quinones-Mateu ME, Ball SC, Marozsan AJ, Torre VS, Albright JL, Vanham G, et al.: A dual infection=competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. J Virol 2000;74:9222-9233.
35. Napravnik S, Edwards D, Stewart P, Stalzer B, Matteson E, and Eron JJ Jr: HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia. J Acquir Immune Defic Syndr 2005;40:34-40.